Special Supplement, May 2023

issue cover

Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn's disease: The Next Frontier?

Published: 2023-05-11

Articles

Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn's Disease The Next Frontier?

Christopher Ma, MD, MPH, FRCPC

2–7
- PDF (en)